Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Apr;16(4):315-324.
doi: 10.1080/14789450.2019.1583105. Epub 2019 Feb 26.

Recent advances in the metabolomic study of bladder cancer

Chandra Sekhar Amara  1 , Venkatrao Vantaku  1 , Yair Lotan  2 , Nagireddy Putluri  1   3
Affiliations
Review

Recent advances in the metabolomic study of bladder cancer

Chandra Sekhar Amara et al. Expert Rev Proteomics. 2019 Apr.

Abstract

Metabolomics is a chemical process, involving the characterization of metabolites and cellular metabolism. Recent studies indicate that numerous metabolic pathways are altered in bladder cancer (BLCA), providing potential targets for improved detection and possible therapeutic intervention. We review recent advances in metabolomics related to BLCA and identify various metabolites that may serve as potential biomarkers for BLCA. Areas covered: In this review, we describe the latest advances in defining the BLCA metabolome and discuss the possible clinical utility of metabolic alterations in BLCA tissues, serum, and urine. In addition, we focus on the metabolic alterations associated with tobacco smoke and racial disparity in BLCA. Expert commentary: Metabolomics is a powerful tool which can shed new light on BLCA development and behavior. Key metabolites may serve as possible markers of BLCA. However, prospective validation will be needed to incorporate these markers into clinical care.

Keywords: BLCA; LC-MS; metabolomics.

PubMed Disclaimer

Conflict of interest statement

Declaration of interest

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

Figures

Figure 1.
Figure 1.
Overview of metabolomics workflow
See this image and copyright information in PMC

References

    1. Ploeg M, Aben KK, Kiemeney LA. The present and future burden of urinary bladder cancer in the world. World J Urol. 2009. June;27(3):289–93. - PMC - PubMed
    1. Lotan Y, Svatek RS, Sagalowsky AI. Should we screen for bladder cancer in a high-risk population?: A cost per life-year saved analysis. Cancer. 2006. September 1;107(5):982–90. - PubMed
    1. Vrooman OP, Witjes JA. Urinary markers in bladder cancer. Eur Urol. 2008. May;53(5):909–16. - PubMed
    1. van Rhijn BW, van der Poel HG, van der Kwast TH. Urine markers for bladder cancer surveillance: a systematic review. Eur Urol. 2005. June;47(6):736–48. - PubMed
    1. Han DS, Zhou W, Seigne JD, et al. Geographic Variation in Cystoscopy Rates for Suspected Bladder Cancer between Female and Male Medicare Beneficiaries. Urology. 2018. August 20. - PMC - PubMed

Publication types

Substances